302440 — SK Bioscience Co Balance Sheet
0.000.00%
- KR₩4tn
- KR₩4tn
- KR₩268bn
- 30
- 12
- 84
- 34
Annual balance sheet for SK Bioscience Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 208,708 | 1,645,663 | 1,475,506 | 1,268,841 | 1,156,508 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 54,008 | 48,135 | 89,661 | 22,342 | 188,396 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 333,902 | 1,837,804 | 1,783,694 | 1,382,969 | 1,576,673 |
| Net Property, Plant And Equipment | 189,479 | 220,983 | 293,057 | 315,923 | 982,607 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 562,232 | 2,110,123 | 2,141,931 | 1,852,439 | 2,843,596 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 180,639 | 459,952 | 380,037 | 135,620 | 310,589 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 298,442 | 508,811 | 400,229 | 148,584 | 1,041,031 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| ESOP Debt Guarantee | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 263,790 | 1,601,312 | 1,741,702 | 1,703,855 | 1,802,565 |
| Total Liabilities & Shareholders' Equity | 562,232 | 2,110,123 | 2,141,931 | 1,852,439 | 2,843,596 |
| Total Common Shares Outstanding |